GlassScriptPhysician profile
Marklyn J Jones
NPI 1003859075
$19,019.40
in general payments reported to CMS, 2019-2025
41 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,206 · 2020: $113 · 2021: $126 · 2022: $2,192 · 2023: $9,658 · 2024: $2,672 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,546 · Travel and Lodging: $3,357 · Food and Beverage: $3,306 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Gift: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,545.94 |
| Travel and Lodging | $3,357.45 |
| Food and Beverage | $3,305.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Gift | $173.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $14,782.55 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Histosonics, INC. | $603.04 | 2025 | |
| Abbvie INC. | $514.16 | 2019-2024 | |
| Janssen Biotech, INC. | $439.77 | 2019-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $265.26 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $202.18 | 2019-2023 | Myrbetriq |
| Telix Pharmaceuticals | $179.69 | 2022-2024 | Illuccix |
| Bayer Healthcare Pharmaceuticals INC. | $171.12 | 2019-2023 | |
| Srs Medical Systems, INC. | $166.56 | 2025 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Pfizer INC. | $151.57 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $144.25 | 2022-2025 | Prolaris |
| Myovant Sciences INC. | $138.30 | 2021-2022 | |
| Procept Biorobotics Corporation | $112.19 | 2022 | |
| Merck Sharp & Dohme LLC | $102.75 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Progenics Pharmaceuticals, INC. | $90.51 | 2022-2024 | Pylarify |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marklyn Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.